News | April 11, 2024
Syntegon showcases oral solid dosage portfolio at Achema
Fluid bed processes: drying, granulating, and coating in just one product container
Fluid bed processes: drying, granulating, and coating in just one product container
The facility has a potential for capacity expansion up to 2 billion tablets/capsules per year
Consolidated entity plans to strengthen specialty pharmaceutical offerings, expand manufacturing capacity, and accelerate global market penetration across emerging regions
Accreditations for Bhayla manufacturing site strengthen the company’s global quality credentials and support expansion of its hormone portfolio into regulated international markets
This certification confirms that the facility complies with Good Manufacturing Practice requirements as referred in the EC Directive
The approval was granted by Agenzia Italiana del Farmaco
Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026
Doshi has established a strong track record in driving quality assurance, regulatory compliance, and formulation excellence across complex pharmaceutical operations
The inspection is now closed, and no regulatory action has been recommended
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
